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Guillain Barré Syndrome (GBS), although an uncommon diagnosis in the emergency department (ED), 
usually presents as one of the more common chief complaints—weakness. In this report we present 
an unusual case of weakness, initially seen in the ED and sent home only to return with worsening 
symptoms and ultimately found to be GBS. [West J Emerg Med. 2010; 11(1):80-82].
CASE REPORT
A 50-year-old male presented to the emergency 
department (ED) with a chief complaint of weakness to the 
upper and lower extremities, increasing over the four days 
prior to arrival and described as an overall “heavy” feeling. 
The patient described a constant, yet gradually increasing 
weakness over this timeframe. He had no previous similar 
symptoms. The patient denied numbness, paresthesias, 
headache, fever, neck stiffness, visual changes, shortness of 
breath, or pain of any kind. The patient stated he had one week 
of watery diarrhea that had resolved two weeks prior to the 
onset of his weakness. The review of systems was negative 
with the exception of the weakness. Past medical history was 
positive for hypertension only. There was no pertinent family 
history. Social history was notable for alcohol intake of two 
to three beers per day. The patient had never smoked or used 
illicit drugs. He was married and lived at home with his wife.
The physical exam was normal with the exception of 
mildly decreased proximal muscle weakness bilaterally 
(4/5), in both upper and lower extremities. The patient 
had no difficulty ambulating; however, he did have mild 
difficulty raising himself from a sitting position. The cranial 
nerves and cerebellar exam were normal. Reflexes were 
normal in both upper and lower extremities on repeated 
exams. A head CT and all labs—including complete blood 
count, electrolytes, liver function, thyroid-stimulating 
hormone, and erythrocyte sedimentation rate—were within 
normal limits. The differential diagnosis included Guillain 
Barré Syndrome (GBS), but this diagnosis was thought 
to be less likely based on the normal reflexes and isolated 
proximal muscle weakness. A neurology consultation was 
requested. After performing their own history and physical 
exam they recommended outpatient clinic evaluation for 
electromyography (EMG). While the etiology of the muscle 
weakness was unclear, they felt GBS was unlikely.
The patient returned to the ED two days later with 
a progression of symptoms and was seen by a different 
physician. He was unable to stand up from a sitting position 
or ambulate without the assistance of two people. On exam 
his proximal muscle strength in upper and lower extremities 
had become notably weaker. In addition, distal muscle 
weakness was now noted. Repeat CBC and electrolytes were 
unchanged. The patient was admitted to the neurology service 
where a lumbar puncture was done that showed a protein 
level of 456mg/L. An EMG was also done, which showed 
a demyelination pattern consistent with GBS. The patient 
was started on intravenous immunoglobulin (IVIg) for five 
days with minimal immediate benefit and was eventually 
transferred to rehab for further physical therapy.
DISCUSSION
Acute ascending weakness was first described by 
Landry in 1859, but the full extent of the disease and its 
characteristics were described by Guillain, Barré and Strohl 
in 1916.1 The disease gained international notoriety under the 
name that remains today, Guillain Barré Syndrome.1 GBS is 
now the world’s most common cause of acute neuromuscular 
paralysis.2 GBS affects about 0.4-2.4/100,000 people annually 
with a bimodal incidence in early and late adulthood, however 
affecting young adults greater then the elderly.2-4 GBS also 
has a slightly greater male preponderance with a ratio of 
1.25-1.5:1.2,5 GBS usually involves a prodromal event such 
as an upper respiratory infection, vaccination, surgery, or 
a gastrointestinal infection. It is thought that up to 88% of 
those affected by GBS have a prodromal infection.6 The most 
commonly linked organism with GBS is Campylobacter Volume XI, no. 1  :  February 2010             81  Western Journal of Emergency Medicine
jejuni, and serology testing has identified the organism in 
as high as 23% of those with GBS.6 One to six weeks after 
the prodromal event, the patient will experience a sub-acute 
ascending peripheral weakness with decreased or absent deep 
tendon reflexes.5
The current diagnostic criteria for GBS are summarized 
in Table 1 (modified from McGillicuddy). Because there 
are numerous entities that can cause weakness and sensory 
deficits, it is imperative that other etiologies be explored 
prior to the diagnosis of GBS. Possible GBS mimics include 
poliomyelitis, myasthenia gravis, electrolyte disturbance, 
botulism, acute myopathy, diphtheria, vasculitis, porphyria, 
tick paralysis, and toxic neuropathy.2,4
Four subtypes of peripheral neuropathy are classified 
under the umbrella of GBS; these are acute inflammatory 
demyelinating polyneuropathy (AIDP), acute motor axonal 
neuropathy (AMAN), acute motor and sensory axonal 
neuropathy (AMSAN), and the Miller Fisher Syndrome 
(MFS).2,5,7 The great majority of those affected with GBS in 
western countries have the AIDP form where macrophages 
invade the myelin sheaths directly and cause denuding 
of the axons impeding conduction along the nerve. In the 
AMAN and AMSAN variants, the pathology consists of 
antibodies to ganglioside antigens that lay on the surface of 
the axon and target the nerve at the nodes of Ranvier and 
the terminals. Several gangliosides share glycoconjugates 
similar to those in the bacterial walls of C. jejuni.5,6 The 
antibodies are formed initially with the C. jejuni bacterial 
infection and later attack the native axons with the same 
ganglioside antigens. This is the common link between GBS 
and C. jejuni. Conduction is altered due to axonal damage 
rather than myelin destruction in the AMAN and AMSAN 
variants.6 The last variant is MFS in which weakness starts 
in the extraocular muscles and can include trunk muscles 
producing ataxia. This variant usually includes antibodies 
to a specific antigen known as GQ1b (measured as anti-
GQ1b antibody).6 In western countries the Motor-Sensory 
GBS accounts for 75% of cases, while purely Motor GBS 
accounts for 20%, and the Miller Fisher Syndrome accounts 
for about 3%.7
Treatment of GBS includes plasmapheresis or 
intravenous immunoglobulin (IVIg), as well as respiratory 
support when needed.2,4-6,8,9 Plasmapheresis and IVIg in 
GBS have been shown to be equal in efficacy; however, the 
ease of use of IVIg has made this the treatment of choice.8-10 
There was controversy regarding whether a steroid regimen 
added benefit to therapy, but current recommendations do 
not support steroid use.9,11 Ventilator support is needed in 
approximately 25% of GBS cases and in cases with more 
rapid progression. With treatment, most will have a linear 
progression of recovery in weeks to months. However, those 
with a more aggressive onset tend to do more poorly with 
recovery, and overall 10-20% are left with a disabling motor 
deficit.5
We report on this patient because he provides a good 
example of the difficulty that continues to exist in the ED with 
respect to the diagnosis of GBS. Both the initial emergency 
physicians (EPs) and the consulting neurologists considered 
and subsequently discounted GBS as the diagnosis. While 
presenting with many of the “classic” characteristics of GBS, 
this patient lacked the two most described characteristics of 
GBS, distal weakness and decreased reflexes. GBS should be 
considered in cases of weakness and paresthesia with careful 
attention to the physical exam. A careful neurologic exam 
including strength and evaluation of reflexes is imperative 
when considering GBS in the differential, especially in the 
ED. In situations where the diagnosis is unclear but where 
GBS is a part of the differential diagnosis—such as the 
one presented here—it is important for the EP to give clear 
discharge instructions with signs to look out for, close follow 
up as an outpatient, and locations for the patient to follow 
up. This must be done with the understanding that the patient 
should return to the ED immediately for any worsening 
symptoms. GBS is the leading cause of acute neuromuscular 
paralysis4 and however rare the presentation, we as EPs 
need to have a keen eye for the presentation characteristics. 
We have the potential to diagnose and intervene early in 
the disease progression, both of which benefit the patient’s 
ultimate outcome.
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Table 1. Guillain Barré Syndrome (GBS) Diagnostic Criteria
Necessary Criteria for the Clinical Diagnosis of GBS
•  Subacutely developing flaccid paralysis
•  Bilateral weakness starts from the onset with a strong ten-
dency for symmetry
•  Myotatic reflexes decrease and usually disappear entirely
•  Other causes for rapidly developing flaccid weakness are 
ruled out
Characteristic Elements for GBS, but with Very Limited 
Diagnostic Value
•  Lumbar puncture with cytoalbuminologic dissociation
•  Electrophysiologic evaluationWestern Journal of Emergency Medicine            82  Volume XI, no. 1  :  February 2010
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